SEC Company Response from IRADIMED CORP (IRMD) (CIK 0001325618) (IRMD) — Jun 19, 2014
IRADIMED CORP (IRMD) (CIK 0001325618)
Date: June 19, 2014 · CIK: 0001325618 · Accession: 0001104659-14-047218
AI Filing Summary & Sentiment
Reasoning
Referenced dates: June 2, 2014, May 22, 2014
Letter
Via EDGAR and Courier United States Securities and Exchange Commission Division of Corporation Finance iRadimed Corporation Registration Statement on Form S-1 Submitted June 18, 2014 CIK No. 00013525618
Dear Ms. Ravitz:
On behalf of iRadimed Corporation, a Delaware corporation (the “Company”, “we”, “us”, “our”), the undersigned is hereby providing an update to one of the Company’s responses to the Securities and Exchange Commission (the “Commission”) comment letter dated May 22, 2014 (the “SEC Letter”).
Comment No. 5 of the SEC Letter requested, in part, “Also, please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.” In Company’s response letter dated June 2, 2014, the Company indicated that, “to the extent the Company presents any written communications to potential investors in reliance on Section 5(d) of the Securities Act …, it will supplementally provide the Staff with copies of such written communication ….”
The Company, concurrently with this letter, will supplementally provide the Staff with the written communications that the Company presented to certain qualified institutional buyers and institutional accredited investors in reliance on Section 5(d) of the Securities Act. The Company advises the Staff that these potential investors were not permitted to retain copies of such written communications.
Should you have any questions or require any additional information, please contact K&L Gates LLP, attention Anh Q. Tran, Esq., by phone at (310) 552-5083, by facsimile at (310) 552-5007, or by e-mail at anh.tran@klgates.com.
Sincerely,
K&L Gates LLP
Show Raw Text
CORRESP 1 filename1.htm June 19, 2014 Via EDGAR and Courier Amanda Ravitz Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: iRadimed Corporation Registration Statement on Form S-1 Submitted June 18, 2014 CIK No. 00013525618 Dear Ms. Ravitz: On behalf of iRadimed Corporation, a Delaware corporation (the “Company”, “we”, “us”, “our”), the undersigned is hereby providing an update to one of the Company’s responses to the Securities and Exchange Commission (the “Commission”) comment letter dated May 22, 2014 (the “SEC Letter”). Comment No. 5 of the SEC Letter requested, in part, “Also, please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.” In Company’s response letter dated June 2, 2014, the Company indicated that, “to the extent the Company presents any written communications to potential investors in reliance on Section 5(d) of the Securities Act …, it will supplementally provide the Staff with copies of such written communication ….” The Company, concurrently with this letter, will supplementally provide the Staff with the written communications that the Company presented to certain qualified institutional buyers and institutional accredited investors in reliance on Section 5(d) of the Securities Act. The Company advises the Staff that these potential investors were not permitted to retain copies of such written communications. Should you have any questions or require any additional information, please contact K&L Gates LLP, attention Anh Q. Tran, Esq., by phone at (310) 552-5083, by facsimile at (310) 552-5007, or by e-mail at anh.tran@klgates.com. Sincerely, K&L Gates LLP /s/ Anh Q. Tran, Esq. Anh Q. Tran, Esq. cc: Julie Sherman, Commission Brian Soares, Commission Roger Susi, Chief Executive Officer, Iradimed Corporation Chris Scott, Chief Financial Officer, Iradimed Corporation Leib Orlanski, K&L Gates LLP